Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
暂无分享,去创建一个
I. Flinn | S. de Vos | K. Foon | K. Ganjoo | C. Slapak | N. Dang | Mitchell R. Smith | J. Wooldridge | B. Pohlman | N. Enas | M. Mapara | A. Forero-Torres | B. Link | D. Cronier | S. Carpenter